PURPOSE: To evaluate whether the presence of metabolic syndrome (MS) in obese adolescents is associated with other comorbidities of obesity METHODS: A total of 85 obese teens (70% female and 30% male) with fasting insulin >25 microU/ml and family history of type 2 diabetes mellitus and/or acanthosis nigricans were studied. Mean age was 15.8 +/- 1.7 years and body mass index (BMI) was 39.3 +/- 6.6 kg/m(2). Of the subjects, 54% were Hispanic and 35% black, 5% white, 5% American Indian, and 1% Asian. Laboratory analysis included fasting lipids, glucose, gamma-glutamyl transpeptidase (GGT), and oral glucose tolerance testing. Additional liver transaminase levels were determined and liver ultrasound (US) was performed to evaluate the presence and severity of fatty liver. RESULTS: All subjects met MS criteria for children for waist circumference, 49% for blood pressure, 54% for high-density lipoprotein, 54% for triglycerides, and 20% for impaired fasting glucose (IFG) or impaired glucose tolerance [IGT]). In all, 47 subjects had three or more MS criteria. BMI was no different between groups with and without MS. Subjects with three or more MS criteria were more likely to have IGT (p = .004), elevated alanine aminotransferase (p = .039), elevated GGT (p = .036), fatty liver on US (p < .001), and more severe fatty liver (p = .001). CONCLUSIONS: Abnormal glucose regulation and evidence of nonalcoholic fatty liver disease (NAFLD) were more common in subjects meeting three criteria for MS than in those meeting fewer criteria. The identification of MS provides value to the primary care provider. Those patients meeting criteria for MS should be evaluated for glucose intolerance and NAFLD.
PURPOSE: To evaluate whether the presence of metabolic syndrome (MS) in obese adolescents is associated with other comorbidities of obesity METHODS: A total of 85 obese teens (70% female and 30% male) with fasting insulin >25 microU/ml and family history of type 2 diabetes mellitus and/or acanthosis nigricans were studied. Mean age was 15.8 +/- 1.7 years and body mass index (BMI) was 39.3 +/- 6.6 kg/m(2). Of the subjects, 54% were Hispanic and 35% black, 5% white, 5% American Indian, and 1% Asian. Laboratory analysis included fasting lipids, glucose, gamma-glutamyl transpeptidase (GGT), and oral glucose tolerance testing. Additional liver transaminase levels were determined and liver ultrasound (US) was performed to evaluate the presence and severity of fatty liver. RESULTS: All subjects met MS criteria for children for waist circumference, 49% for blood pressure, 54% for high-density lipoprotein, 54% for triglycerides, and 20% for impaired fasting glucose (IFG) or impaired glucose tolerance [IGT]). In all, 47 subjects had three or more MS criteria. BMI was no different between groups with and without MS. Subjects with three or more MS criteria were more likely to have IGT (p = .004), elevated alanine aminotransferase (p = .039), elevated GGT (p = .036), fatty liver on US (p < .001), and more severe fatty liver (p = .001). CONCLUSIONS: Abnormal glucose regulation and evidence of nonalcoholic fatty liver disease (NAFLD) were more common in subjects meeting three criteria for MS than in those meeting fewer criteria. The identification of MS provides value to the primary care provider. Those patients meeting criteria for MS should be evaluated for glucose intolerance and NAFLD.
Authors: Scott M Grundy; James I Cleeman; Stephen R Daniels; Karen A Donato; Robert H Eckel; Barry A Franklin; David J Gordon; Ronald M Krauss; Peter J Savage; Sidney C Smith; John A Spertus; Fernando Costa Journal: Circulation Date: 2005-09-12 Impact factor: 29.690
Authors: G Marchesini; S Avagnina; E G Barantani; A M Ciccarone; F Corica; E Dall'Aglio; R Dalle Grave; P S Morpurgo; F Tomasi; E Vitacolonna Journal: J Endocrinol Invest Date: 2005-04 Impact factor: 4.256
Authors: Miriam V Louthan; Judy A Theriot; Ellen Zimmerman; John T Stutts; Craig J McClain Journal: J Pediatr Gastroenterol Nutr Date: 2005-10 Impact factor: 2.839
Authors: James B Meigs; Peter W F Wilson; Caroline S Fox; Ramachandran S Vasan; David M Nathan; Lisa M Sullivan; Ralph B D'Agostino Journal: J Clin Endocrinol Metab Date: 2006-05-30 Impact factor: 5.958
Authors: B Palmentieri; I de Sio; V La Mura; M Masarone; R Vecchione; S Bruno; R Torella; M Persico Journal: Dig Liver Dis Date: 2006-05-22 Impact factor: 4.088
Authors: Thomas Jensen; Manal F Abdelmalek; Shelby Sullivan; Kristen J Nadeau; Melanie Green; Carlos Roncal; Takahiko Nakagawa; Masanari Kuwabara; Yuka Sato; Duk-Hee Kang; Dean R Tolan; Laura G Sanchez-Lozada; Hugo R Rosen; Miguel A Lanaspa; Anna Mae Diehl; Richard J Johnson Journal: J Hepatol Date: 2018-02-02 Impact factor: 25.083
Authors: Emily R Perito; Tabitha Vase; Rageshree Ramachandran; Andrew Phelps; Kuang-Yu Jen; Robert H Lustig; Vickie A Feldstein; Philip Rosenthal Journal: Liver Transpl Date: 2017-07 Impact factor: 5.799
Authors: Alexandre Abilio de Souza Teixeira; Camila O Souza; Luana A Biondo; Loreana Sanches Silveira; Edson A Lima; Helena A Batatinha; Adriane Pereira Araujo; Michele Joana Alves; Sandro Massao Hirabara; Rui Curi; José Cesar Rosa Neto Journal: Inflammopharmacology Date: 2018-02-15 Impact factor: 4.473
Authors: Emily E Ventura; Christianne J Lane; Marc J Weigensberg; Claudia M Toledo-Corral; Jaimie N Davis; Michael I Goran Journal: J Pediatr Date: 2009-06-24 Impact factor: 4.406
Authors: Jennifer L Trilk; Andrew Ortaglia; Steven N Blair; Matteo Bottai; Timothy S Church; Russell R Pate Journal: Med Sci Sports Exerc Date: 2013-04 Impact factor: 5.411